CASC3 and non-Hodgkin lymphoma: Clinical trials applying BTZ solo or combined with other anti-cancer agents in phases I, II, and III on non-Hodgkin lymphoma, myeloid leukemia, and multiple myeloma patients have demonstrated promising responses, considering response rate, time to progression, and survival.26-28 Several investigations have shown the potential of BTZ for treating fibrosis, such as kidney fibrosis.29,30 BTZ’s potential antifibrotic actions have attracted interest in fatty liver and fibrosis correlated with inflammation.